- Home
- APRE vs TCRT Comparison
APRE vs TCRT Comparison
Compare APRE & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- TCRT
- Stock Information
- Founded
- APRE 2006
- TCRT 1998
- Country
- APRE United States
- TCRT United States
- Employees
- APRE N/A
- TCRT N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- TCRT Health Care
- Exchange
- APRE Nasdaq
- TCRT Nasdaq
- Market Cap
- APRE 8.3M
- TCRT 7.0M
- IPO Year
- APRE 2019
- TCRT N/A
- Fundamental
- Price
- APRE $1.39
- TCRT $2.62
- Analyst Decision
- APRE Strong Buy
- TCRT
- Analyst Count
- APRE 1
- TCRT 0
- Target Price
- APRE $20.00
- TCRT N/A
- AVG Volume (30 Days)
- APRE 141.8K
- TCRT 1.3M
- Earning Date
- APRE 11-07-2025
- TCRT 11-14-2025
- Dividend Yield
- APRE N/A
- TCRT N/A
- EPS Growth
- APRE N/A
- TCRT N/A
- EPS
- APRE N/A
- TCRT N/A
- Revenue
- APRE $841,012.00
- TCRT $6,000.00
- Revenue This Year
- APRE N/A
- TCRT $5,680,500.00
- Revenue Next Year
- APRE N/A
- TCRT N/A
- P/E Ratio
- APRE N/A
- TCRT N/A
- Revenue Growth
- APRE N/A
- TCRT N/A
- 52 Week Low
- APRE $1.31
- TCRT $1.31
- 52 Week High
- APRE $5.00
- TCRT $6.20
- Technical
- Relative Strength Index (RSI)
- APRE 42.40
- TCRT 45.47
- Support Level
- APRE $1.31
- TCRT $2.62
- Resistance Level
- APRE $1.46
- TCRT $2.82
- Average True Range (ATR)
- APRE 0.09
- TCRT 0.17
- MACD
- APRE -0.01
- TCRT -0.05
- Stochastic Oscillator
- APRE 22.11
- TCRT 19.08
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.